Loading...
•
Jun 30
Annovis Bio Q2 2025 Earnings Report
Annovis Bio reported a reduced net loss in Q2 2025 as both R&D and G&A expenses declined year-over-year.
Key Takeaways
In Q2 2025, Annovis Bio lowered its operating expenses and narrowed its net loss compared to the previous year. The company continued to invest in its pivotal Phase 3 trial for Alzheimer's and expanded its IP portfolio. A stronger balance sheet supported its operational momentum, backed by improved cash reserves.
Net loss narrowed to $6.22 million from $5.02 million in Q2 2024.
R&D expenses decreased to $5.16 million, down from $5.79 million YoY.
G&A expenses dropped significantly to $1.11 million from $1.98 million YoY.
Cash position strengthened to $17.13 million at quarter-end.
Annovis Bio
Annovis Bio
Forward Guidance
Annovis continues to prioritize enrollment and execution of its Alzheimer's Phase 3 trial while expanding scientific visibility and securing IP for its lead asset.
Positive Outlook
- 76 U.S. clinical sites secured for pivotal Phase 3 Alzheimer's study.
- Nearly 200 patients screened with steady enrollment momentum.
- Successful global transfer of crystal buntanetap patent families.
- Four new scientific presentations delivered at AAIC 2025.
- Cash balance rose to $17.1 million by quarter-end.
Challenges Ahead
- Net losses continue amid trial spending.
- Stock-based compensation not disclosed in Q2 2025.
- No revenue reported as development remains in clinical stages.
- Warrant fair value adjustment created small non-cash loss.
- Diluted EPS showed no improvement despite improved net loss.